UCB SA (UCB.BR) Stock Fundamental Analysis
EBR:UCB - Euronext Brussels - BE0003739530 - Common Stock - Currency: EUR
UCB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. UCB has only an average score on both its financial health and profitability. UCB is growing strongly while it is still valued neutral. This is a good combination! This makes UCB very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year UCB was profitable.
In the past year UCB had a positive cash flow from operations.
Each year in the past 5 years UCB has been profitable.
In the past 5 years UCB always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 6.14%, UCB is doing good in the industry, outperforming 61.54% of the companies in the same industry.
The Return On Equity of UCB (10.62%) is comparable to the rest of the industry.
The Return On Invested Capital of UCB (8.79%) is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for UCB is significantly below the industry average of 13.62%.
The last Return On Invested Capital (8.79%) for UCB is above the 3 year average (4.35%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROIC | 8.79% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
UCB's Profit Margin of 17.31% is amongst the best of the industry. UCB outperforms 82.69% of its industry peers.
UCB's Profit Margin has been stable in the last couple of years.
UCB's Operating Margin of 23.31% is fine compared to the rest of the industry. UCB outperforms 67.31% of its industry peers.
UCB's Operating Margin has declined in the last couple of years.
The Gross Margin of UCB (71.52%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
UCB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, UCB has about the same amount of shares outstanding.
The number of shares outstanding for UCB has been increased compared to 5 years ago.
UCB has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.33 indicates that UCB is not in any danger for bankruptcy at the moment.
The Altman-Z score of UCB (4.33) is better than 73.08% of its industry peers.
UCB has a debt to FCF ratio of 3.29. This is a good value and a sign of high solvency as UCB would need 3.29 years to pay back of all of its debts.
UCB has a Debt to FCF ratio of 3.29. This is in the better half of the industry: UCB outperforms 65.38% of its industry peers.
UCB has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of UCB (0.30) is better than 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Altman-Z | 4.33 |
ROIC/WACC1.17
WACC7.49%
2.3 Liquidity
UCB has a Current Ratio of 1.36. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.36, UCB is in line with its industry, outperforming 48.08% of the companies in the same industry.
UCB has a Quick Ratio of 1.36. This is a bad value and indicates that UCB is not financially healthy enough and could expect problems in meeting its short term obligations.
UCB's Quick ratio of 0.99 is in line compared to the rest of the industry. UCB outperforms 57.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 211.38%, which is quite impressive.
Measured over the past 5 years, UCB shows a small growth in Earnings Per Share. The EPS has been growing by 5.34% on average per year.
Looking at the last year, UCB shows a quite strong growth in Revenue. The Revenue has grown by 17.14% in the last year.
Measured over the past years, UCB shows a small growth in Revenue. The Revenue has been growing by 4.60% on average per year.
EPS 1Y (TTM)211.38%
EPS 3Y0.25%
EPS 5Y5.34%
EPS Q2Q%2599.02%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
3.2 Future
UCB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.20% yearly.
UCB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.43% yearly.
EPS Next Y62.35%
EPS Next 2Y44.49%
EPS Next 3Y34.31%
EPS Next 5Y30.2%
Revenue Next Year16.59%
Revenue Next 2Y14.8%
Revenue Next 3Y14.13%
Revenue Next 5Y12.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 34.40 indicates a quite expensive valuation of UCB.
The rest of the industry has a similar Price/Earnings ratio as UCB.
The average S&P500 Price/Earnings ratio is at 29.35. UCB is around the same levels.
UCB is valuated quite expensively with a Price/Forward Earnings ratio of 25.69.
The rest of the industry has a similar Price/Forward Earnings ratio as UCB.
UCB's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.4 | ||
| Fwd PE | 25.69 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UCB is on the same level as its industry peers.
UCB's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.85 | ||
| EV/EBITDA | 18.08 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of UCB may justify a higher PE ratio.
UCB's earnings are expected to grow with 34.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.55
PEG (5Y)6.44
EPS Next 2Y44.49%
EPS Next 3Y34.31%
5. Dividend
5.1 Amount
With a yearly dividend of 0.50%, UCB is not a good candidate for dividend investing.
UCB's Dividend Yield is comparable with the industry average which is at 2.86.
Compared to an average S&P500 Dividend Yield of 2.33, UCB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.5% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years5
Div Non Decr Years5
5.3 Sustainability
UCB pays out 24.32% of its income as dividend. This is a sustainable payout ratio.
UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP24.32%
EPS Next 2Y44.49%
EPS Next 3Y34.31%
EBR:UCB (3/7/2025, 7:00:00 PM)
188.5
-3.55 (-1.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.15%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap36.67B
Analysts75.2
Price Target210.97 (11.92%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.5% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP24.32%
Div Incr Years5
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.73%
PT rev (3m)14.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.34%
EPS NY rev (3m)8.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)1.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.4 | ||
| Fwd PE | 25.69 | ||
| P/S | 5.96 | ||
| P/FCF | 39.85 | ||
| P/OCF | 29.52 | ||
| P/B | 3.66 | ||
| P/tB | 75.6 | ||
| EV/EBITDA | 18.08 |
EPS(TTM)5.48
EY2.91%
EPS(NY)7.34
Fwd EY3.89%
FCF(TTM)4.73
FCFY2.51%
OCF(TTM)6.39
OCFY3.39%
SpS31.63
BVpS51.56
TBVpS2.49
PEG (NY)0.55
PEG (5Y)6.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROCE | 10.38% | ||
| ROIC | 8.79% | ||
| ROICexc | 10.16% | ||
| ROICexgc | 50.51% | ||
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% | ||
| FCFM | 14.95% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexcg growth 3Y-25.87%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Debt/EBITDA | 1.43 | ||
| Cap/Depr | 50.23% | ||
| Cap/Sales | 5.23% | ||
| Interest Coverage | 8.96 | ||
| Cash Conversion | 59.86% | ||
| Profit Quality | 86.39% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 4.33 |
F-Score9
WACC7.49%
ROIC/WACC1.17
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)211.38%
EPS 3Y0.25%
EPS 5Y5.34%
EPS Q2Q%2599.02%
EPS Next Y62.35%
EPS Next 2Y44.49%
EPS Next 3Y34.31%
EPS Next 5Y30.2%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
Revenue Next Year16.59%
Revenue Next 2Y14.8%
Revenue Next 3Y14.13%
Revenue Next 5Y12.43%
EBIT growth 1Y178.99%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year135.81%
EBIT Next 3Y49.79%
EBIT Next 5Y33.54%
FCF growth 1Y106.74%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y63.21%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%